Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of statin and aspirin in preparation of medicine for treating blood high viscosity syndrome

A technology for aspirin and stagnation, which is applied in the field of pharmacy to achieve the effects of reducing the specific viscosity of plasma, low price and improving compliance

Inactive Publication Date: 2007-05-23
BEIJING HUAANFO BIOMEDICAL RES CENT
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology provides combinations of different agents for reducing both high sheer stress or lowered platelet count caused by certain medical conditions such as acute coronary syndrome. These combined therapies are effective at controlling these symptoms without causing unwanted side effectes like other pharmaceuticals used alone.

Problems solved by technology

This patent describes various technical problem addressed during treatments involving excessively accumulating fluid called extracellular fluids due to elevating levels of certain substances like lipids and other metabolites found within these body systems. These conditions result in poor circulatory health outcomes including impairment of immune response leading to chronoinfarcts and potential life threatening consequences. There is an urgent medical goal to develop new methods and compositions containing different types of agents specifically targeted towards this issue without affecting their safety properties over existing products.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 aspirin simvastatin double capsule

[0022] Prescription composition:

[0023] Simvastatin capsule granule portion Simvastatin 1mg

[0024] Sodium Lauryl Sulfate 1%

[0025] Starch 96mg

[0026] Micronized silica gel 2%

[0027] The production process takes simvastatin, sodium lauryl sulfate and starch and mixes them uniformly by equal volume incremental dilution method, uses 5% PVP aqueous solution as binder, adopts wet granulation process, granulates, and sieves after drying at 40 degrees. points, spare.

[0028] Aspirin capsule granule portion Aspirin 75mg

[0029] Starch 72mg

[0030] Micro Silica Gel 3mg

[0031] The production process takes aspirin and starch and mixes them uniformly by the equal-volume incremental dilution method, uses 5% PVP ethanol solution as a binder, adopts a wet granulation process, granulates, sieves after dryin...

Embodiment 2

[0032] Embodiment 2 aspirin simvastatin bilayer tablet

[0033] Prescription composition:

[0034] Simvastatin tablet portion Simvastatin 1mg

[0035] Sodium Lauryl Sulfate 1%

[0036] Starch 96mg

[0037] Micronized silica gel 2%

[0038] The production process takes simvastatin, sodium lauryl sulfate and starch and mixes them uniformly by equal volume incremental dilution method, uses 5% PVP aqueous solution as binder, adopts wet granulation process, granulates, and sieves after drying at 40 degrees. points, spare.

[0039] Aspirin Tablet Portion Aspirin 75mg

[0040] Starch 72mg

[0041] Micro Silica Gel 3mg

[0042] The production process takes aspirin and starch and mixes them uniformly by the equal-volume incremental dilution method, uses 5% PVP ethanol solution as the binder, adopts the wet granulation process, granulates, granulates after drying at 40 degrees, and then sieves and com...

Embodiment 3

[0043] Embodiment 3 aspirin simvastatin bilayer tablet

[0044] Composition of the prescription:

[0045] Part of Simvastatin Tablets Simvastatin 10mg

[0046] Sodium Lauryl Sulfate 1%

[0047] Starch 87mg

[0048] Micronized silica gel 2%

[0049] The production process takes simvastatin, sodium lauryl sulfate and starch and mixes them uniformly by equal volume incremental dilution method, uses 5% PVP aqueous solution as binder, adopts wet granulation process, granulates, and sieves after drying at 40 degrees. Divide, press tablet.

[0050] Aspirin tablet portion Aspirin 50mg

[0051] Starch 48mg

[0052] Micronized silica gel 2%

[0053] The production process takes metformin hydrochloride and starch to be uniformly mixed by the equal-volume incremental dilution method, with 5% PVP aqueous solution as the binder, adopts wet granulation process, granulates, granulates, sieves and compresses...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for treating hyperviscosemia, in particular the use of statins antihyperglycemic medicaments and aspirin in preparing medicament for the treatment of hyperviscosemia, wherein the content of aspirin is 25-250mg, the statins antihyperglycemic medicament is selected from simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, rosuvastatin and pitavastatin.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner BEIJING HUAANFO BIOMEDICAL RES CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products